Interface Biologics Completes Pre-IND Meeting with U.S. FDA
Interface Biologics announced a positive pre-IND (Investigational New Drug) meeting with the U.S. FDA for its novel dexamethasone intravitreal implant for the treatment of posterior inflammatory eye diseases.